Since its founding in 2012, SDS Life Science has grown into a multi-disciplinary team of handpicked specialists with regulatory and scientific knowledge in medicinal product development and statistics. Our ambition is to guide our clients in transforming their research hypotheses into full clinical studies. We adopt a holistic approach in collaboration with our clients to provide the best solutions for each unique project. Our passion is to solve those tricky questions which have no obvious answers.
We combine excellence and experience
Jens Hansson is the CEO and chairman of the board and a highly experienced company builder making use of a multitude of competences achieved from almost 30 years of mid- and top management positions within the financial and manufacturing industries. He is a strong leader with high team-working ethics, bringing together talent and empowering team members to reach established goals effectively. Jens leadership is built on inspiration, responsiveness and stability, all of which will be of much importance in SDS growth journey.
Anna Torrång has a BSc in Statistics from the University of Linköping, Sweden, and a long and broad experience (>25 years) from the pharmaceutical industry and epidemiological research at the Karolinska Institute in Stockholm. Within AstraZeneca she worked as a Global Product Statistician in projects within neuroscience and as a Group Manager for Biostatisticians. Her main expertise lies within clinical development, and the design and statistical analysis of clinical trials. Anna has worked at SDS since 2013, primarily as a senior biostatistical consultant in drug development and as the Director for SDS Biostatistics.
Susanne holds an MSc in Pharmacy from Uppsala University and has more than 25 years of drug development experience from the pharmaceutical and life science industry. Her main expertise lies within epidemiology and Real World Evidence and she is passionate about finding the best solutions for our client's needs for excellent RWE/HEOR-studies.
Susanne has worked many years in the Nordics as well as other European countries and the US. She started working at SDS Life Science in 2021 as Director for Real World Evidence.
Erika Spens started working at SDS Life Science in 2021 as director for regulatory affairs. Erika has 15+ years of experience in the pharmaceutical industry, both within small and larger enterprises. Before she started working at SDS, she held a position as director for global regulatory affairs at a parent company, working with early development, market registrations, and post-approval activities in Europe, the US, and the rest of the world. Furthermore, she has experience in project management of development programs and large business collaborations. Erika holds a Master of Science from Uppsala University and a Ph.D. in bioprocess technology from The Royal Institute of Technology (KTH) in Sweden. Erika's passion is to develop regulatory strategies with the best chance of success for a given product in development.
Christina joined SDS Life Science in 2021 as director for Drug Development. She holds a Master of Science in Pharmacy and a PhD in Pharmaceutics from Uppsala University and has + 20 years of experience in the life science industry. Christina has worked with formulation and product development, process development and manufacturing of most dosage forms from early phase, during registration and life cycle management post-authorization. Previous employments include Senior Scientist within drug development at AstraZeneca and management positions within production, clinical trials, pharmaceutical development and business development at APL as well as the Swedish MPA.
Anna Sandholm holds a PhD in Environmental Chemistry from Stockholm University, in the scientific area of Drug Metabolism and Pharmacokinetics. Anna has extensive experience from the pharmaceutical industry and from academic research.
Anna has worked extensively with candidate drug selection and early-to-late drug development across a broad range of indications. She has significant knowledge of regulatory guidelines and recommendations, and a solid understanding of how to best apply them while maintaining focus on the overall scientific rationale.
Her core competence is nonclinical and early clinical projects from a scientific, strategic and regulatory perspective. She has worked at SDS since 2012, primarily as a senior consultant in drug development and as Director for SDS Nonclinical and DMPK.
Anna is a founder of Scandinavian Development Services (SDS) Group and holds a PhD in Biostatistics from Karolinska Institutet, Stockholm. Her varied experience comes from work within regulatory authorities, the pharmaceutical industry and academic research. She has long-standing industry experience as a consultant within regulatory affairs and drug clinical trials at Pfizer Pharmaceuticals, Pharmacia & Upjohn and Zeneca Pharmaceuticals, to name a few. Anna's expertise lies within clinical development and she is particularly interested in merging statistical and regulatory knowledge to create studies better suited for regulatory needs.
Lars Lund-Roland has a marketing and business background and works as a management and business consultant. Lars has recently been CEO of Bringwell AB(pub), a Nordic health and welfare company listed in Stockholm, that commercializes OTC pharmaceuticals, nutrition and food supplements. He has also been Managing Director of MSD Norway (Merck & Co Inc. subsidiary) for 10 years and has more than twenty-five years’ experience from various executive positions within marketing and sales at Merck. He also serves as board member of Vaccibody AS and has served as member of the board of Targovax ASA, another immunotherapy company in the oncology field; as well as the board of Infodoc AS and Health Tech AS, two Norwegian health technology companies and the Norwegian Association of Pharmaceutical Manufacturers.